Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018

About Non-Hodgkin Lymphoma (NHL) and its Diagnostic Procedures
Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body’s lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests.
TechNavio's analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.
TechNavio's report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ EMEA
‧ APAC
Key Vendors
‧ Bristol Myers Squibb Co.
‧ Celgene Corp.
‧ Eli Lilly and Co.
‧ F. Hoffman La-Roche Ltd.
‧ GlaxoSmithKline plc
Other Prominent Vendors

‧ Accredo Health Group Inc.
‧ Baxter International Inc.
‧ Bayer AG
‧ Cephalon Inc.
‧ Eisai Pharmaceuticals Inc.
‧ Genelabs Technologies Inc.
‧ Hospira Inc.
‧ Johnson & Johnson
‧ Merck & Co. Inc.
‧ Millenium Pharmaceuticals Inc.
‧ Pacira Pharmaceuticals Inc.
‧ Pfizer Inc.
‧ Sanofi SA
‧ Teva Pharmaceuticals Inc.
Key Market Driver
‧ Availability of Biosimilars at a Reduced Price.
‧ For a full, detailed list, view our report.
Key Market Challenge
‧ High Cost of NHL Drugs.
‧ For a full, detailed list, view our report.
Key Market Trend
‧ Dominance of NHL Market by Biologics.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report

‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
08. Market Segmentation by Type of Therapy
08.1.1 Chemotherapy
08.1.2 Targeted Therapy
09. Pipeline Portfolio
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Bristol-Myers Squibb Co.
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Product Segmentation
19.1.4 Sales by Geography
19.1.5 Business Strategy
19.1.6 Key Information
19.1.7 SWOT Analysis
19.1.8 Strengths
19.1.9 Weaknesses
19.1.10 Opportunities
19.1.11 Threats
19.2 Celgene Corp.
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Strategy
19.2.4 Business Segmentation by Revenue 2011-2013
19.2.5 Sales by Geography
19.2.6 Key Developments
19.2.7 SWOT Analysis
19.2.8 Strengths
19.2.9 Weaknesses
19.2.10 Opportunities
19.2.11 Threats
19.3 Eli Lilly and Co.
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Business Strategy
19.3.7 Key Developments
19.3.8 SWOT Analysis
19.3.9 Strengths
19.3.10 Weaknesses
19.3.11 Opportunities
19.3.12 Threats
19.4 F. Hoffmann La Roche Ltd.
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Information
19.4.8 SWOT Analysis
19.4.9 Strengths
19.4.10 Weaknesses
19.4.11 Opportunities
19.4.12 Threats
19.5 GlaxoSmithKline plc
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Pipeline Products
19.5.7 Business Strategy
19.5.8 Key Information
19.5.9 SWOT Analysis
19.5.10 Strengths
19.5.11 Weaknesses
19.5.12 Opportunities
19.5.13 Threats
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Non-Hodgkin Lymphoma therapeutics market (in US$ billions)
Exhibit 3: Global Non-Hodgkin Lymphoma Therapeutics Market by Type of Therapy
Exhibit 4: Pipeline Portfolio of Global Non-Hodgkin Lymphoma Therapeutics Market
Exhibit 5: Global NHL Therapeutics Market by Geographical Segmentation 2013
Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 8: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 9: Celgene Corp.: Sales by Geography 2013
Exhibit 10: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 11: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 12: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 17: GlaxoSmithKline Plc: Business Segmentation 2013
Exhibit 18: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)
Exhibit 19: GlaxoSmithKline Plc: Sales by Geography 2013
Exhibit 20: GlaxoSmithKline plc: Pipeline Products 2013